Cargando…
Conjunctivitis : symptoms, treatment, and prevention /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Nova Biomedical Books,
[2010]
|
| Colección: | Eye and vision research developments series.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- CONJUNCTIVITIS: SYMPTOMS, TREATMENT AND PREVENTION ; CONTENTS ; PREFACE ; ALLERGIC DISORDERS OF THE CONJUNCTIVA ; ABSTRACT ; 1. INTRODUCTION ; 2. IMMUNOLOGY RELEVANT TO ALLERGIC EYE DISEASE ; 2.1. Introduction ; 2.2. Lymphocyte Activation ; 2.3. Immune Hypersensitivity Reaction in Allergic Eye Diseases ; 2.3.1. Antibody-Mediated Hypersensitivity in Allergic Eye Diseases ; 2.3.1.1. IgG-Mediated Hypersensitivity Immune Reactions ; 2.3.1.2. IgE-Mediated Hypersensitivity Immune Reactions ; 2.3.2. T-Lymphocite-Mediated Hypersensitivity in Allergic Eye Diseases.
- 3. CELLS AND MEDIATORS IN ALLERGIC EYE DISEASE 3.1. Antigen ; 3.2. Antibodies ; 3.3. B Lymphocytes ; 3.4. Antigen Presenting Cells ; 3.5. Dendritic Cells ; 3.6. Major histocomapibility complex (MHC) ; 3.7. Tryptase ; 3.8. Histamine ; 3.9. Langerhans Cells (LC) ; 3.10. Mast Cells ; 3.11. Prostaglandins ; 3.12. Leukotrienes ; 3.13. Adhesion Molecules ; 3.14. Neutrophils ; 3.15. Complement ; 3.16. Matrix Metalloproteinases (MMP) ; 3.17. Growth Factors ; 3.18. Eosinophils ; 3.19. Epithelial Cells ; 3.20. Fibroblast ; 3.21. T-Lymphocytes.
- 3.22. Co-Stimulatory Molecules and Receptors 3.24. Chemokines ; 4. PHARMACOLOGIC THERAPY OF ALLERGIC EYE DISEASE ; 4.1. Vasoconstrictors ; 4.2. Antihistamines ; 4.3. Mast Cell Stabilizers ; 4.4. Multimodal or Dual Acting Agents ; 4.5. Nonsteroidal Anti-Inflammatory Drugs (NSAID) ; 4.6. Steroids ; 4.7. Anti-Metabolites ; 4.8. Immunomodulators ; 5. SPECIFIC ALLERGIC EYE DISEASES ; 5.1. Allergic conjunctivitis ; 5.2. Vernal Keratoconjunctivitis ; 5.3. Giant Papillary Conjunctivitis ; 5.4. Atopic Keratoconjunctivitis ; 5.5. Contact Ocular Allergy ; CONCLUSION.
- ACKNOWLEDGMENT REFERENCES ; NOVEL DRUG DELIVERY APPROACHES IN DRY EYE SYNDROME THERAPY ; ABSTRACT ; ABBREVIATIONS ; 1. INTRODUCTION ; 2. LACHRYMAL FUNCTIONAL UNIT AND DRY EYE SYNDROME ; 2.1. Causes of the Dry Eye ; 2.2. Signs and Symptoms of the Dry Eye ; 3. THERAPEUTIC APPROACHES OF THE DRY EYE SYNDROME ; 3.1. Current Therapeutic Strategies ; 3.1.1. Tear Substitution: Artificial Tear Substitutes and Lubricants ; 3.1.2. Tear Preservation ; 3.1.2.1. Occlusion of the Tear Drainage System ; 3.1.2.2. Other Methods of Tear Preservation ; 3.1.3. Pharmacological Stimulation of Natural Tears.
- 3.1.4. Treatment of the Underlying Causes of Dry Eye Disease 3.1.4.1. Cyclosporine A ; 3.1.4.2. Topical Corticosteroids ; 3.1.4.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs) ; 3.1.4.4. Systemic Tetracyclines ; 3.1.4.5. Sexual Hormones ; 3.1.4.6. Topical Vitamin A ; 3.1.4.7. Topical Autologous Serum ; 3.1.4.8. Omega-6; 3.1.4.9. Botulinum Toxin A ; 3.1.4.10. Acupuncture ; 3.1.4.11. Antiviral Agents ; 3.2. Novel Therapeutic Strategies ; 3.2.1. Polymeric Nanoparticles ; 3.2.1.1. Natural Polymers ; 3.2.1.2. Polymeric Coating of Various Carrier Systems ; 3.2.2. Solid Lipid Nanoparticles.